View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
July 13, 2011

Advaxis Completes Patient Enrolment in Neoplasia Study

Advaxis has concluded enrolment of the first 40-subject cohort in the dose-ranging Phase II study of ADXS-HPV, an immunotherapy for cervical intraepithelial neoplasia. The randomised, single blind, placebo-controlled Phase II study is designed to evaluate the drug's safety and efficacy

By cms admin

Advaxis has concluded enrolment of the first 40-subject cohort in the dose-ranging Phase II study of ADXS-HPV, an immunotherapy for cervical intraepithelial neoplasia.

The randomised, single blind, placebo-controlled Phase II study is designed to evaluate the drug’s safety and efficacy in up to three dose cohorts.

Advaxis chairman and CEO Thomas Moore said that the six-month follow-up evaluation for this first cohort will be completed by January 2012, and the low dose results are expected to be released in early 2012.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology